Reversible ventricular arrythmia induced by dasatinib

KEY CLINICAL MESSAGE: Ventricular arrhythmias induced by dasatinib are rare events, but physicians in charge of chronic myeloid leukemia patients should be aware of such potential complications and the need for regular ECG controls during treatment with tyrosine kinase inhibitors.

Detalles Bibliográficos
Autores principales: Spechbach, Hervé, Morel, Philippe, Lorenzini, Kuntheavy Ing, Besson, Marie, Gétaz, Laurent, Sunthorn, Henri, Chalandon, Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184536/
https://www.ncbi.nlm.nih.gov/pubmed/25356203
http://dx.doi.org/10.1002/ccr3.5
_version_ 1782337859413344256
author Spechbach, Hervé
Morel, Philippe
Lorenzini, Kuntheavy Ing
Besson, Marie
Gétaz, Laurent
Sunthorn, Henri
Chalandon, Yves
author_facet Spechbach, Hervé
Morel, Philippe
Lorenzini, Kuntheavy Ing
Besson, Marie
Gétaz, Laurent
Sunthorn, Henri
Chalandon, Yves
author_sort Spechbach, Hervé
collection PubMed
description KEY CLINICAL MESSAGE: Ventricular arrhythmias induced by dasatinib are rare events, but physicians in charge of chronic myeloid leukemia patients should be aware of such potential complications and the need for regular ECG controls during treatment with tyrosine kinase inhibitors.
format Online
Article
Text
id pubmed-4184536
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-41845362014-10-29 Reversible ventricular arrythmia induced by dasatinib Spechbach, Hervé Morel, Philippe Lorenzini, Kuntheavy Ing Besson, Marie Gétaz, Laurent Sunthorn, Henri Chalandon, Yves Clin Case Rep Case Reports KEY CLINICAL MESSAGE: Ventricular arrhythmias induced by dasatinib are rare events, but physicians in charge of chronic myeloid leukemia patients should be aware of such potential complications and the need for regular ECG controls during treatment with tyrosine kinase inhibitors. Blackwell Publishing Ltd 2013-10 2013-07-31 /pmc/articles/PMC4184536/ /pubmed/25356203 http://dx.doi.org/10.1002/ccr3.5 Text en © 2013 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Reports
Spechbach, Hervé
Morel, Philippe
Lorenzini, Kuntheavy Ing
Besson, Marie
Gétaz, Laurent
Sunthorn, Henri
Chalandon, Yves
Reversible ventricular arrythmia induced by dasatinib
title Reversible ventricular arrythmia induced by dasatinib
title_full Reversible ventricular arrythmia induced by dasatinib
title_fullStr Reversible ventricular arrythmia induced by dasatinib
title_full_unstemmed Reversible ventricular arrythmia induced by dasatinib
title_short Reversible ventricular arrythmia induced by dasatinib
title_sort reversible ventricular arrythmia induced by dasatinib
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184536/
https://www.ncbi.nlm.nih.gov/pubmed/25356203
http://dx.doi.org/10.1002/ccr3.5
work_keys_str_mv AT spechbachherve reversibleventriculararrythmiainducedbydasatinib
AT morelphilippe reversibleventriculararrythmiainducedbydasatinib
AT lorenzinikuntheavying reversibleventriculararrythmiainducedbydasatinib
AT bessonmarie reversibleventriculararrythmiainducedbydasatinib
AT getazlaurent reversibleventriculararrythmiainducedbydasatinib
AT sunthornhenri reversibleventriculararrythmiainducedbydasatinib
AT chalandonyves reversibleventriculararrythmiainducedbydasatinib

Ejemplares similares